The future outlook on allergen immunotherapy in children: 2018 and beyond

Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as...

Full description

Bibliographic Details
Main Authors: Stefania Arasi, Giovanni Corsello, Alberto Villani, Giovanni Battista Pajno
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Italian Journal of Pediatrics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13052-018-0519-4
id doaj-31b3779a8f99474f93542267e92cbfe0
record_format Article
spelling doaj-31b3779a8f99474f93542267e92cbfe02020-11-25T01:11:58ZengBMCItalian Journal of Pediatrics1824-72882018-07-014411910.1186/s13052-018-0519-4The future outlook on allergen immunotherapy in children: 2018 and beyondStefania Arasi0Giovanni Corsello1Alberto Villani2Giovanni Battista Pajno3Allergy Unit- Department of Pediatrics, University of MessinaDepartment of Maternal and Child Health, University of PalermoPediatric and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCSAllergy Unit- Department of Pediatrics, University of MessinaAbstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT might be a strategy to prevent the development of a new sensitization or of a (new) allergic disease. However, there are still some methodological criticisms, such as: a) the regimen of administration and the amount of the maintenance dose are both largely variable; b) the protocols of administration are not standardized; c) the description and classification of side effects is variable among studies and needs to be standardized; d) quality of life and evaluation of health economics are overall missing. All these aspects make difficult to compare each study with another. In addition, the content of major allergen(s) remains largely variable among manufacturers and the availability of AIT products differences among countries. The interest and the attention to AIT treatment are currently fervent and increasing. Well-designed studies are awaited in the near future in order to overcome the current gaps in the evidence and furtherly promote implementation strategies.http://link.springer.com/article/10.1186/s13052-018-0519-4Allergen-specific immunotherapyAllergic rhinitisAllergyChildrenFood allergyIgE-mediated allergic diseases
collection DOAJ
language English
format Article
sources DOAJ
author Stefania Arasi
Giovanni Corsello
Alberto Villani
Giovanni Battista Pajno
spellingShingle Stefania Arasi
Giovanni Corsello
Alberto Villani
Giovanni Battista Pajno
The future outlook on allergen immunotherapy in children: 2018 and beyond
Italian Journal of Pediatrics
Allergen-specific immunotherapy
Allergic rhinitis
Allergy
Children
Food allergy
IgE-mediated allergic diseases
author_facet Stefania Arasi
Giovanni Corsello
Alberto Villani
Giovanni Battista Pajno
author_sort Stefania Arasi
title The future outlook on allergen immunotherapy in children: 2018 and beyond
title_short The future outlook on allergen immunotherapy in children: 2018 and beyond
title_full The future outlook on allergen immunotherapy in children: 2018 and beyond
title_fullStr The future outlook on allergen immunotherapy in children: 2018 and beyond
title_full_unstemmed The future outlook on allergen immunotherapy in children: 2018 and beyond
title_sort future outlook on allergen immunotherapy in children: 2018 and beyond
publisher BMC
series Italian Journal of Pediatrics
issn 1824-7288
publishDate 2018-07-01
description Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT might be a strategy to prevent the development of a new sensitization or of a (new) allergic disease. However, there are still some methodological criticisms, such as: a) the regimen of administration and the amount of the maintenance dose are both largely variable; b) the protocols of administration are not standardized; c) the description and classification of side effects is variable among studies and needs to be standardized; d) quality of life and evaluation of health economics are overall missing. All these aspects make difficult to compare each study with another. In addition, the content of major allergen(s) remains largely variable among manufacturers and the availability of AIT products differences among countries. The interest and the attention to AIT treatment are currently fervent and increasing. Well-designed studies are awaited in the near future in order to overcome the current gaps in the evidence and furtherly promote implementation strategies.
topic Allergen-specific immunotherapy
Allergic rhinitis
Allergy
Children
Food allergy
IgE-mediated allergic diseases
url http://link.springer.com/article/10.1186/s13052-018-0519-4
work_keys_str_mv AT stefaniaarasi thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT giovannicorsello thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT albertovillani thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT giovannibattistapajno thefutureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT stefaniaarasi futureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT giovannicorsello futureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT albertovillani futureoutlookonallergenimmunotherapyinchildren2018andbeyond
AT giovannibattistapajno futureoutlookonallergenimmunotherapyinchildren2018andbeyond
_version_ 1725168407882498048